Supplanting Chemotherapy in Cancer Treatment-Clay Siegall

Inspirery interview illuminates into the professional life of Clay Siegall since the founding of Seattle Genetic in 1998. Dr, Clay as the founder and CEO of Seattle genetics focuses on production and distribution of targeted therapy drugs for ailments that for a long time have not improved concerning mortality rate. As a BSC graduate in Zoology from The University of Maryland as well as a Ph.D in genetics, Siegall has competently led the biotech firm to the top of therapy industry.

Seattle Genetics is on record to be the first firm in the industry to develop the first antibody-drug conjugate approved by FDA. According to Dr. Clay obtaining FDA approval is not only a long process but also expensive. He mentions that usually, only one out of ten proposed drugs gets approval thus a company has to take care of all the other associating expenses of the remaining drugs. Despite his original interest in medicine, Siegall mentions that the interest was established after a family member fell sick.

Siegall Genetics makes money through selling their proprietary drugs as well as from production partnerships and technology licensing. Clay Siegall points out hard work and good sales strategies to the success of the company.

Clay Siegall has over thirty years experience in the therapy industry where he specializes in cancer treatment. The father’s death when he was 24 years led to his decision and focus on finding other modes of treatment other than chemotherapy. Dr. Siegall performance and growth to the apex of the therapy industry is attributed not only to his solid science background in college but also twenty years experience in therapeutic drug development. Before the existence of Siegall Genetics, Clay worked with Bristol-Myers Squibb Pharmaceutical Research Institute as a scientist and research investigator.

Currently, he serves in various companies. He is the director of Ultragenyx Pharmaceutical Inc, director at Alder Biopharmaceuticals Inc, director of Washington Biotechnology and Biomedical Association, and sits on the board of directors at Fred Hutchinson Cancer Research Business Alliance. Besides, Dr. Siegall is an author with over seventy publications and 15 patents. The scientist, author, and entrepreneur believes that people do not differ in intellect but work habits that determine success.